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Abstract
Randomised trials are a central component of all evidence-informed health care systems and the evidence coming
from them helps to support health care users, health professionals and others to make more informed decisions
about treatment. The evidence available to trialists to support decisions on design, conduct and reporting of
randomised trials is, however, sparse. Trial Forge is an initiative that aims to increase the evidence base for trial
decision-making and in doing so, to improve trial efficiency.
One way to fill gaps in evidence is to run Studies Within A Trial, or SWATs. This guidance document provides a brief
definition of SWATs, an explanation of why they are important and some practical ‘top tips’ that come from existing
experience of doing SWATs. We hope the guidance will be useful to trialists, methodologists, funders, approvals agencies
and others in making clear what a SWAT is, as well as what is involved in doing one.
Introduction
Randomised trials are a central component of all
evidence-informed health care systems and they form a
body of evidence that can help health care users, health
professionals, policy-makers and others make informed
choices about the effectiveness of treatments and therap-
ies that they use and provide. The same is not true for
trial design, conduct and reporting decisions, which are
generally uninformed by evidence because there is little
relevant evidence to turn to.
Trial Forge (www.trialforge.org) [1] is an initiative that
aims to increase the evidence base for trial decision-
making and, in doing so, to improve trial efficiency. One
way to fill gaps in evidence is to run Studies Within A
Trial, or SWATs. Descriptions of SWATs have been
published [2, 3] but here we provide some guidance that
provides a brief definition of a SWAT, an explanation of
why they are important and some practical ‘top tips’ that
come from existing experience of doing SWATs. We hope
the guidance will be useful to trialists, methodologists,
funders, approvals agencies and others in making clear
what a SWAT is, as well as what is involved in doing one.
We encourage them to use the text freely on their own
websites and materials, with appropriate
acknowledgement.
The text is based on discussions held during and after
a 1-day meeting in Aberdeen, UK on 23 March 2017 as
part of the Trial Forge initiative. This paper is the first
Trial Forge Guidance document and there will be more
guidance documents in the future, each providing what
we hope is clear help and guidance around an issue
relevant to improving the evidence base for trial
decision-making. Trial methodologists and other
stakeholders will be consulted to determine the topic
areas and scope for future guidance.
What is a Study Within A Trial (SWAT)?
A SWAT is a self-contained research study that has been
embedded within a host trial with the aim of evaluating
or exploring alternative ways of delivering or organising
a particular trial process.
Why do we need to do SWATs?
The need for randomised trials to evaluate the effects of
health care interventions, such as new drugs and other
* Correspondence: streweek@mac.com
1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Treweek et al. Trials  (2018) 19:139 
https://doi.org/10.1186/s13063-018-2535-5
treatments, is a familiar concept to people working in
health and health research. The result of the trial provides
evidence on how effective (or ineffective) the intervention
is, helping both practitioners and health care users to
make well-informed decisions about using it. These trials
are central to improvements in health and social care.
Therefore, it is essential that the trials themselves are
done in the most effective ways and one way to do this is
to use the same types of evaluation to investigate and
improve the processes of how we do randomised trials.
Unfortunately, only a small number of such studies have
been done and there is very little evidence to allow
researchers to make well-informed decisions about how to
do their trials [1]. This means that researchers doing trials,
funders paying for them and patients taking part in them
cannot always be sure that the way the trial is being done
is as effective and efficient as it could be. The most
obvious example of this is that the evidence available to
support trial teams to recruit patients to their trials is very
thin, despite recruitment being a recognised problem for
many trials [4, 5] and being identified as the top priority
for research into trial methods [6].
One way of increasing this evidence base is to do a Study
Within A Trial (SWAT) [2, 3]. SWATs evaluate alternative
ways of doing a trial process (e.g. recruiting patients,
helping them to stay in the study, or reporting the findings)
to provide evidence about how to improve the process.
Key features of a typical SWAT
 It seeks to resolve important uncertainties about the
processes used in trials
 It is embedded within a host trial
 It must not affect the scientific integrity of the host
trial, its rationale or outcome measures
 It should have a formal protocol, just like the host
trial
 It can be evaluated in a single trial but is well-suited
for running across more than one host trial, either
at the same time or sequentially
 It will provide data to inform the design and
conduct of future trials but might also provide data
to inform decisions about the ongoing host trial
For some practical considerations regarding SWATs,
see Table 1. The information in the table comes mainly
from experience with SWATs in the UK and Ireland but
is likely to be useful for SWATs planned in other
countries too.
An example of a SWAT
Most trials have a Participant Information Leaflet (PIL),
which tells a potential participant about the trial. The trial
team uses this to offer information to potential trial
participants in a way that it hopes will also help recruit-
ment (and perhaps retention) whilet adhering to ethical
standards.
The Systematic Techniques for Assisting Recruitment
to Trials (START) programme (http://research.bmh.man-
chester.ac.uk/mrcstart/) developed a SWAT to evaluate
the effect of a bespoke, tailored and user-tested PIL on
recruitment compared with a standard PIL. The bespoke
method of developing a PIL is expensive so it is important
to know how much, if any, difference it makes to the trial.
For instance, if the aim is to increase recruitment, it is es-
sential to know that recruitment is indeed increased with
the bespoke PIL compared with a standard PIL before
using it in a future trial. The SWAT has already been
evaluated in several trials (see, for example [7, 8]) and the
emerging results are shown in Fig. 1. This meta-analysis
shows that the current estimate for the effect on
recruitment is small and not statistically significant: 1%
improvement (95% confidence interval, − 1–2%).
In other words, the bespoke PIL had little or no effect on
recruitment compared with a standard PIL. By
approaching investigators, encouraging them to embed an
evaluation of the two types of PIL into their trials and then
coordinating the analysis of data from those trials that did,
the START programme’s coordinated, collaborative
approach of embedding a SWAT evaluation in trials
involving over 6600 people now provides an evidence base
for researchers trying to decide on whether to develop a
bespoke PIL for their trial.
Other examples of questions that could be addressed
in SWATs include:
 Comparing the effect of different financial incentives
to encourage patients to complete a questionnaire
used to collect trial outcomes
 Determining whether recruitment is boosted if
non-responders to postal invitations to join a trial
are reminded by telephone
 Evaluating the effect on recruitment and retention
of a two-stage Participant Information Leaflet (i.e.
the leaflet is delivered to participants in two parts: a
short ‘key points’ version together with a longer
version containing more detail) compared with a
standard, single-stage leaflet
 Evaluating the effect on data quality of providing site
staff with face-to-face data entry training compared
with Skype or video-conference training
 Exploring which type of information participants
think would best recognise the value of their
contribution to the host trial results
There are plenty of uncertainties around how we
should do trials, so it is highly likely that a trial team can
find something that is interesting to them and worth
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investigating in a SWAT. For example, the Prioritising
Recruitment in Randomised Trials (PRioRiTy) project
(http://priorityresearch.ie/) generated a list of priority
areas for recruitment research and many of these could
be addressed by SWATs.
What happens to SWAT results?
Just as health researchers have a responsibility to make the
findings of their clinical trials available, the findings from
Table 1 Practical things to consider when planning a Study
Within A Trial (SWAT)
Cost
• SWATs need not be expensive; our experience is that many are
likely to cost between £5000 and £10,000. Ideally, they should be
built into the host trial from the start and the associated costs can
be included in the budget for the host trial. If the findings of the
SWAT will be reported in a standalone publication in an author-pays
open-access journal, the costs of this will be need to be budgeted for
Randomisation
• Whether randomisation is needed depends on the question being
asked. If the intention is to evaluate the effect of alternative ways of
doing a trial process, then the alternatives being compared should
be allocated at random. This may not always be possible and another
allocation method (e.g. before and after the new alternative) can be
used but in most cases this will weaken confidence in the results.
However, if the question being asked is not focused on measuring
effect sizes (e.g. it could be concerned with understanding why
something is done the way it is) then randomisation is likely to be
inappropriate and other qualitative methods would be required.
Randomisation is not a defining feature of a SWAT
• Randomisation can be by a separate process to that used for the
host trial randomisation
Ethics
• Ethical approval guidelines and regulations for conducting research
in humans vary between countries. Depending on the specific SWAT
protocol being evaluated, it is advised that the researcher checks
national guidance and discusses whether ethical approval is
required with their institutional or local ethical committee
• It is likely that some, but not all, SWATs will need ethical and other
approvals. Clinical trials of medicinal products in the EU are provided
for in Directive 2001/20/EC of the European Parliament. Such trials
require research ethical approval and it is likely that any SWAT
within a host trial subject to the EU directive will require ethical review
• Ethical governance of clinical trials outside of the directive, i.e.
non-medicinal products for human use vary between countries. In
the UK for instance, SWATs within non-medicinal product trials that
involve only trial staff will not normally need UK NHS ethical
approval (but may need institutional review), while it is likely that
those that involve NHS patients will. In the Republic of Ireland, there
is a system of national approval for trials of medicinal products but
not for non-medicinal products and, therefore, for the latter ethical
approval is usually sought from sites conducting the host trial and/
or from the SWAT principal investigator’s host institution. If the
SWAT was planned at the same time as the host trial, then it could
be included in the application for ethical approval of the host trial.
Trial Forge has a collection of material that has been used before to
obtain ethical approval for a SWAT, which it adds to its own SWAT
packages. Contact info@trialforge.org for more details
• SWATs are generally low risk and it is rare for them to impose
additional burden or risk on participants and consequently it will not
usually be necessary to get individual consent from participants.
Indeed, in many cases individual consent may not be appropriate. It
may confuse patients as to what they are consenting to, and may
impact on their behaviour if they are aware that different
recruitment methods are being tested, confounding the evaluation
• SWATs aimed at staff, but which directly affect patients/participants,
may need NHS or other ethical review (e.g. studies that change
what recruiters say to potential participants, or who says it to them).
Where there is any doubt researchers should contact the Health
Research Authority (HRA)/Devolved Nation’s REC administrative body
to check whether NHS ethical review is required. In the Republic of
Ireland, researchers should check with the ethics committee
approving the host trial and with any site in which the trial will be
conducted
Table 1 Practical things to consider when planning a Study
Within A Trial (SWAT) (Continued)
• In the UK NHS Research Ethics Committee approval is not normally
required for research only involving staff who are recruited by virtue
of their professional role. However, where such studies are led from
England and involves the NHS in England ‘HRA approval’ may be
required (see http://www.hra.nhs.uk/about-the-hra/our-plans-and-
projects/assessment-approval/ for further information)
Analysis
• The analysis of SWATs might be simple (such as the comparison of
two proportions) and might be done by members of the trial team
other than a senior statistician
• Sample size calculations for SWATs can be done in the usual way
using estimates of minimum important differences that the
investigators or others consider appropriate. The size of a SWAT is
constrained by the host trial. The size of a recruitment SWAT will
generally be larger than the host trial sample size (the constraint is
the size of the patient population approached, not recruited). Other
SWATs (such as those on retention) will be limited to the actual host
trial sample. It is highly unlikely that the size of the host trial will be
changed for the benefit of a SWAT. SWATs are designed for future
meta-analysis. In other words, while an individual SWAT may be
underpowered, a meta-analysis of several well-done SWATs evaluating
the same intervention and following the same protocol can provide
compelling evidence for trial process decision making. As with all
meta-analysis, judgements need to be made about whether it is
sensible to combine studies done in different populations, disease
areas and settings. This issue will be the topic of future Trial Forge
Guidance
• SWATs exploring qualitative questions about how a trial process is
delivered, organised or perceived will be analysed using a suitable
qualitative analysis method
Implementing the SWAT
• Some of the extra work needed for a SWAT (e.g. putting additional
materials or incentives into envelopes along with information
leaflets) might be done by temporary staff, or existing staff who
have a lull in the work for their own trial. For other SWATs there
might be little additional work involved (for example, using mail
merge software to generate different invitation letters). However,
confidentiality/data protection issues may limit who can do the
work, depending on its content and the potential for identifying
participants to those who would not otherwise have lawful access
to personal identifiable information
• They need not run for the whole duration of the host trial so any
extra work may be both modest and short-term
Publication
• The findings of the SWAT should be put into the public domain and
should be accessible by others. This might be possible through
inclusion in the report of the host trial (with appropriate
signposting, perhaps in the abstract, to highlight its presence), in a
standalone dedicated publication or through inclusion in a relevant
systematic review
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SWATs should be made public, so that the evidence base
available for future decisions can increase. The findings
can then be picked up by systematic reviewers and others
who synthesise research evidence. The person doing the
SWAT can facilitate this by, for example, contacting those
who have done a relevant Cochrane Methodology Review
(who will be updating it), to let them know about the
SWAT. This means that even if the SWAT is not published
separately itself, its results can be incorporated into the
review.
SWAT results can also directly inform decisions within
the host trial where uncertainty exists as to the best
method to use for a particular process. The BEEP trial
(https://www.journalslibrary.nihr.ac.uk/programmes/hta/
126712/#/) is using a SWAT [9] and an interim analysis to
help make a decision about the retention strategies to be
used in the trial. A web-based trial linked to antibiotic pre-
scribing also used a SWAT to make a decision about the
best way to invite participants to take part in the second
stage of the trial [10]. Although both of these SWATs
provide useful information for other trials, they were
designed to directly inform process decisions taken within
the host trial.
The SWAT repository
Queen’s University Belfast in Northern Ireland hosts a
SWAT repository (go.qub.ac.uk/SWAT-SWAR), which
contains a list of prepared SWAT outlines. A form to
register a new SWAT is also available online at http://
www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrials-
MethodologyResearch/SWATSWARInformation/Applica-
tionForms/SWATApplication/. Registering SWATs on the
repository helps to avoid unnecessary duplication of effort
and provides other researchers with ideas for how they
might test the processes they will use in their own clinical
trial.
The PRioRiTy repository
If your SWAT addresses one of the top 20 PRioRiTy
research questions it can also be added to the PRioRiTy
online repository (http://priorityresearch.ie/) which is a
collection of ongoing research specific to recruitment to
trials. This repository is hosted by the Health Research
Board – Trials Methodology Research Network in Ireland.
Ideally, these methodology studies should be included in
both the PRioRiTy and the SWAT repository to help
people to find them.
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